Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Allot
ALLT
$388M
| $21.6M | 0.02% |
2,063,255
+66,900
| +3% | +$709K |
|
777
Haverty Furniture Companies
HVT
$450M
| $21.5M | 0.02% |
1,343,206
+7,711
| +0.6% | +$113K |
|
778
Brookfield
BN
$111B
| $21.5M | 0.02% |
+1,219,607
| New | +$21.4M |
|
779
Brink's
BCO
$4.72B
| $21.4M | 0.02% |
+471,200
| New | +$21.5M |
|
|
CHA
780
DELISTED
China Telecom Corporation, LTD
CHA
| $21.4M | 0.02% |
762,000
+161,700
| +27% | +$5.13M |
|
781
Iridium Communications
IRDM
$5.27B
| $21.4M | 0.02% |
840,200
-295,500
| -26% | -$6.93M |
|
|
SNR
782
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
| $21.4M | 0.02% |
5,899,406
-1,010,401
| -15% | -$3.04M |
|
783
IDEX
IEX
$17.6B
| $21.3M | 0.02% |
134,925
-108,600
| -45% | -$16.6M |
|
|
PFC
784
DELISTED
Premier Financial Corp. Common Stock
PFC
| $21.3M | 0.02% |
1,205,212
-267,003
| -18% | -$4.32M |
|
785
Celldex Therapeutics
CLDX
$3.35B
| $21.3M | 0.02% |
1,637,175
+466,988
| +40% | +$2.07M |
|
786
Northrop Grumman
NOC
$81.6B
| $21.2M | 0.02% |
68,900
+62,900
| +1,048% | +$20.6M |
|
787
MDU Resources
MDU
$4.27B
| $21.2M | 0.02% |
2,510,575
-2,030,271
| -45% | -$16.9M |
|
788
Philip Morris
PM
$294B
| $21.2M | 0.02% |
302,200
-209,200
| -41% | -$15.3M |
|
789
Weyerhaeuser
WY
$17.9B
| $21.2M | 0.02% |
942,281
-596,361
| -39% | -$12.1M |
|
790
Descartes Systems
DSGX
$6.62B
| $21.1M | 0.02% |
399,400
-262,819
| -40% | -$11.7M |
|
791
Graham Holdings Company
GHC
$4.97B
| $21.1M | 0.02% |
61,541
+31,143
| +102% | +$10.9M |
|
|
RETA
792
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $21M | 0.02% |
134,700
+29,600
| +28% | +$4.5M |
|
793
A10 Networks
ATEN
$1.96B
| $21M | 0.02% |
3,076,733
+587,300
| +24% | +$3.94M |
|
794
Steven Madden
SHOO
$3.46B
| $20.9M | 0.02% |
844,567
+94,595
| +13% | +$2.21M |
|
|
GLUU
795
DELISTED
Glu Mobile Inc.
GLUU
| $20.8M | 0.02% |
2,248,100
+2,233,600
| +15,404% | +$19M |
|
796
Smith & Nephew
SNN
$12.6B
| $20.7M | 0.02% |
544,150
-177,100
| -25% | -$7.02M |
|
797
Utah Medical Products
UTMD
$230M
| $20.7M | 0.02% |
233,714
+2,200
| +1% | +$197K |
|
798
HealthStream
HSTM
$849M
| $20.7M | 0.02% |
935,807
+258,107
| +38% | +$5.98M |
|
799
AMERISAFE
AMSF
$504M
| $20.6M | 0.02% |
337,193
+35,800
| +12% | +$2.23M |
|
800
Simpson Manufacturing
SSD
$8B
| $20.6M | 0.02% |
244,400
-110,600
| -31% | -$8.16M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.